Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 3-Drug H. pylori Eradication Therapies to Get Further Indication for Chronic Gastritis; Big Boost to PPI Market Expected
March 5, 2013
- Daiichi Sankyo to Set Up Biologics Oversight Function within R&D Division in Order to Enhance Biopharmaceutical Research Level
March 5, 2013
- Teva Pharma, Nippon Kayaku Receive Approval of Japan’s Second G-CSF Biosimilar
March 5, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
March 4, 2013
- Pfizer Japan’s Ethical Drug Sales Dip 4.2% on Lipitor Patent Expiry: FY2012 Earnings
March 4, 2013
- Extra Concurrent-Use Indications Approved for DPP-4 Inhibitor Equa: Novartis
March 4, 2013
- Merck Serono Appoints Koichi Katsura as Head of R&D Japan
March 4, 2013
- Abilify Once-Monthly Injection Approved in US: Otsuka
March 4, 2013
- ARB Sales Apparently Peak Out in Japan Antihypertensive Market
March 1, 2013
- Astellas to Adopt International Financial Reporting Standards as of March 2014
March 1, 2013
- DSP’s US Subsidiary Sunovion Announces FDA Acceptance of NDA Resubmission for Epilepsy Treatment Stedesa
March 1, 2013
- Takeda to Develop New Compounds for Autoimmune Diseases Jointly with Resolve Therapeutics of US
March 1, 2013
- Taiho Files for Novel Anticancer Agent TAS-102 in Japan
March 1, 2013
- BMKK, Pfizer Japan Launch, Copromote Anti-Xa Agent Eliquis
March 1, 2013
- Shionogi Receives FDA Approval for Dyspareunia Treatment, Plans its Launch in June
February 28, 2013
- Gilenya Achieved Blockbuster Status in 2012; Canagliflozin Will Be Next: Pres. Tsuchiya of MTPC
February 28, 2013
- MTPC Files for Expanded Combination-Use Indication for DPP-4 Inhibitor Tenelia
February 28, 2013
- GSK Launches Anti-Malaria Drug Malarone in Japan
February 27, 2013
- Takeda Recalling Renal Anemia Drug Omontys in US after Death Reports
February 26, 2013
- Combined Sales of Januvia and Glactiv Break 110 Billion Yen in 2012: IMS Japan
February 26, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…